-+ 0.00%
-+ 0.00%
-+ 0.00%

Agomab Therapeutics Director David R Epstein Reports $27,850 Common Share Acquisition

PUBT·11/19/2026 11:32:58
Listen to the news
Agomab Therapeutics Director David R Epstein Reports $27,850 Common Share Acquisition
  • Agomab Therapeutics director David R. Epstein purchased 5,000 common shares at $5.57 per share.
  • The purchase increased his direct holdings to 59,980 common shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001445826-26-000020), on November 19, 2026, and is solely responsible for the information contained therein.